Peginesatide is a novel investigational synthetic, PEGylated peptidic compound that binds to and activates the erythropoietin receptor and thus acts as an ESA. Affymax and Takeda are collaborating
In the study, 25 asymptomatic HAE patients with a history of frequent attacks received once weekly administrations of 50 U/kg of Ruconest for 8 weeks. The study results
Pfizer and Protalix BioTherapeutics had entered into an agreement to develop and commercialise Taliglucerase alfa On 30 November 2009. Under the terms of the agreement, Pfizer received exclusive
Under the contract, Selcia’s chemists and biologists will continue to provide integrated drug discovery services to support Gilead‘s liver disease research programmes. Gilead Research senior vice president William
Simcor is indicated to reduce elevated total-C, LDL-C, Apo B, non-HDL-C, TG, or to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia when treatment with simvastatin
Cognistar is a nutriment for the brain which regulates and improves nerve cell metabolism, promotes synapse generation, induces nerve cell differentiation, and protects nerve cells against damages by
The tribunal awarded Basilea $130m, including lost milestones, other damages and interest. Ceftobiprole is an anti-MRSA broad-spectrum cephalosporin antibiotic exhibiting activity against a wide spectrum of Gram-positive bacteria,
Under this alliance, GSK will supply bulk vaccine and provide technology and expertise to enable Binnopharm to undertake the secondary manufacture, including filling and packaging of a number
Veeva Systems is a SaaS-based CRM solutions for the global life sciences industry. Veeva Systems president and CEO Peter Gassner said that they are excited to enter into
The new patent application was filed for novel dosing combinations of RVX-208 and leading statin therapeutics based on the analysis of the Phase II study data. The study
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.